ESMO Gynae 2025 | What is the future role of bevacizumab in pretreated cervical cancer?
Alberto Farolfi, MD, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Dino Amadori, Meldola, Italy, comments on the evolving role of bevacizumab in cervical cancer. Patients who are fit for treatment should receive a combination of bevacizumab and an atezolizumab, based on the promising results of the BEATcc trial (NCT03556839). This approach could lead to high progression-free survival and response rates. This interview took place at 2025 European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Taking out the data on the BEATcc trial that analyzed the atezo and bev combination in cervical cancer, we saw that this kind of patient achieved a very high progression-free survival and also responses. So I think that due to this kind of results, our analysis, if the patient is fit for this kind of treatment, should receive all the treatments, so bev and the atezo checkpoint inhibitor...
Taking out the data on the BEATcc trial that analyzed the atezo and bev combination in cervical cancer, we saw that this kind of patient achieved a very high progression-free survival and also responses. So I think that due to this kind of results, our analysis, if the patient is fit for this kind of treatment, should receive all the treatments, so bev and the atezo checkpoint inhibitor.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK-Tesaro, MSD; Financial Interests, Personal, Advisory Board: Janssen, AstraZeneca, GSK.
